AFMD

AFM13-202 (REDIRECT)

CD-30 positive peripheral T cell lymphoma (PTCL)

Phase 2 Intermin Data

Exp Date

H1 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: AFM13-202 (REDIRECT) for CD-30 positive peripheral T cell lymphoma (PTCL) Phase 2 interim Data

  • Clinical Trial (NCT04101331) : Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2 Interim Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • H1 2021 


PRIOR DATA/EVENTS

PRESS RELEASES

MECHANISM OF ACTION 

  • AFM13 is a first-in-class tetravalent, bispecific innate cell engager that specifically binds to CD30 on tumor cells and to CD16A on NK cells and macrophages. AFM13 is being developed in peripheral T cell lymphoma (pTCL) and in other CD30-positive lymphomas. AFM13 has shown a favorable safety profile and signs of therapeutic efficacy as a monotherapy in CD30-positive non-Hodgkin lymphoma with cutaneous manifestation. In addition, data from a combination study of AFM13 with Merck’s anti-PD-1 antibody Keytruda® (pembrolizumab) in Hodgkin lymphoma (HL) supports proof of principle for the combination of NK cell engagement with checkpoint inhibition. AFM13 has been granted orphan drug designation by the U.S. Food and Drug Administration for HL.

  • (Source AFMDebsite)

Updated by MV

AFM13, REDIRECT, AFMD, cancer, peripheral T Cell Lymphoma (PTCL), CD30 positive

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon